新疆乌鲁木齐市管教所人员HCV感染的流行病学调查与其感染因素研究
|
摘要
目的:了解某管教所人员中丙型肝炎病毒感染状况及其影响因素。方法:采用横断面研究方法,抽取乌鲁木齐市某管教所全体男性人员523名及乌鲁木齐市某乡男性1034名为调查对象,对其进行问卷调查,内容包括:人口学特征、吸毒行为、性行为、有无输血、纹身等行为。同时采集所有调查者血清标本,用ELISA方法检测血清中丙型肝炎病毒感染标志物抗-HCV,资料用SPSS13.0软件进行统计分析。结果:调查对象管教所人群平均年龄20.31±6.78岁,对照组平均年龄24.60±12.29岁。管教所及对照组人员均以青少年为主,汉族人数接近于少数民族,文化程度均偏低。管教所与对照组间抗-HCV阳性率汉族、维吾尔族人员差异有统计学意义(P<0.05);14～年龄组差异有统计学意义(P<0.05);初中组差异有统计学意义(P<0.05)。管教所内不同文化程度抗-HCV阳性率差异有统计学意义(P<0.05)。523份管教所血清中抗-HCV总阳性率为2.67%,除外吸毒人员抗-HCV总阳性率为1.80%,对照组抗-HCV阳性率为0.39%。管教所人员不安全性行为抗-HCV阳性率与对照组差异有统计学意义(P<0.05)。管教所人群经多因素Logistic回归分析表明:管教所内吸毒人员是HCV感染的高危人群。结论:经各可能相关感染因素分析研究,不安全性行为可能与HCV感染有关,管教所男性吸毒人员是HCV感染的高危因素。因此,对该人群应采取有效措施进行严格管理,积极开展HCV感染宣传教育,这对于控制和消除丙型肝炎传染源,预防HCV在社会人群中的传播具有重要的流行病学意义。
Objective: TO determine the status of hepatitis C virus infection and its risk factors among the reformatory population. Methods: Uses the cross-sectional study, extracts the Urumqi reformatory all masculine being in custody personnel 523 and one township male 1034 named investigation objects, and carries on the questionnaire survey. the content includes: the demography characteristic, the behavior of take drugs, the sex act, whether there is to transfuse blood, behaviors and so on tattoo, simultaneously gathers all surveyor blood serum specimen, with the ELISA method examination blood serum in hepatitis C virus infection designated object anti--HCV, the material carries on the statistical analysis with the SPSS13.0 software. Result: Survey reformatory population with an average age of 20.31±6.78, the control group with average age of 24.60±12.29. reformatory officers and the control group are mainly young people, the number closer to the Han ethnic minorities, have low education level. The reformatory and control group anti--HCV the masculine gender rate Han Nationality, the Uygur national minority personnel difference has statistics significance (P<0.05); 14~ age group difference have statistics significance (P<0.05); The junior middle school group difference has statistics significance (P<0.05); In the reformatory the different years of schooling anti--HCV masculine gender rate difference has statistics significance (P<0.05). The anti--HCV total masculine gender rate of the 523 reformatory serums is 2.67%, The anti--HCV total masculine gender rate of the exception taking drugs personnel is 1.80%, The anti--HCV masculine gender rate of the control group is 0.39%. The reformatory population unsafe sex act anti--HCV masculine gender rate and the control group difference have statistics significance (P<0.05). The reformatory crowd indicated after the multi-factor Logistic regression analysis: In the reformatory the taking drugs personnel are the HCV infection high-risk groups. Conclusion: After the infective agent analytical study, the unsafe sex act is possible related with HCV infection, the reformatory masculine taking drugs personnel are the HCV infection high-risk factors. Therefore, should take the effective action to this crowd to carry on the strict management, carries out the HCV infection public education positively, this regarding controls and eliminates the hepatitis C origin of infection, prevents HCV to have the important epidemiology significance in the social crowd's dissemination.
Objective: TO determine the status of hepatitis C virus infection and its risk factors among the reformatory population. Methods: Uses the cross-sectional study, extracts the Urumqi reformatory all masculine being in custody personnel 523 and one township male 1034 named investigation objects, and carries on the questionnaire survey. the content includes: the demography characteristic, the behavior of take drugs, the sex act, whether there is to transfuse blood, behaviors and so on tattoo, simultaneously gathers all surveyor blood serum specimen, with the ELISA method examination blood serum in hepatitis C virus infection designated object anti--HCV, the material carries on the statistical analysis with the SPSS13.0 software. Result: Survey reformatory population with an average age of 20.31±6.78, the control group with average age of 24.60±12.29. reformatory officers and the control group are mainly young people, the number closer to the Han ethnic minorities, have low education level. The reformatory and control group anti--HCV the masculine gender rate Han Nationality, the Uygur national minority personnel difference has statistics significance (P<0.05); 14~ age group difference have statistics significance (P<0.05); The junior middle school group difference has statistics significance (P<0.05); In the reformatory the different years of schooling anti--HCV masculine gender rate difference has statistics significance (P<0.05). The anti--HCV total masculine gender rate of the 523 reformatory serums is 2.67%, The anti--HCV total masculine gender rate of the exception taking drugs personnel is 1.80%, The anti--HCV masculine gender rate of the control group is 0.39%. The reformatory population unsafe sex act anti--HCV masculine gender rate and the control group difference have statistics significance (P<0.05). The reformatory crowd indicated after the multi-factor Logistic regression analysis: In the reformatory the taking drugs personnel are the HCV infection high-risk groups. Conclusion: After the infective agent analytical study, the unsafe sex act is possible related with HCV infection, the reformatory masculine taking drugs personnel are the HCV infection high-risk factors. Therefore, should take the effective action to this crowd to carry on the strict management, carries out the HCV infection public education positively, this regarding controls and eliminates the hepatitis C origin of infection, prevents HCV to have the important epidemiology significance in the social crowd's dissemination.
引文
[1] Rehermann B, NascimbeniM. Immunology of hepatitis B virus and hepatitis C virus infection [J]. Nat Rev Immunol, 2005, 5 (3) : 215 - 229.
[2]刘锡光主编.病毒性肝炎实验诊断学,第二版.北京:人民卫生出版社, 1999.
[3] Perz JF, Farrington LA, Pecoraro C, et al. Estimated global prevalence of hepatitis C virus infection. 42nd Annual Meeting of the Infectious Diseases Society of America ; Boston, MA, USA; Sept 302Oct 3, 2004.
[4] 2007年亚太肝病学会有关丙型肝炎诊断?处理和治疗的共识.传染病信息, 2007, 20(3) R 187-189.
[5] Freeman AL, Zekry A, Whybin LR, et al. Hepatitis C prevalence among Australianinjeetingdrugusersinthe19705andProfilesofvirusgenotyPein the19705 and 19905. Med-J-Aust. 2000Jun19:172(12):588-91.
[6]石爽,庄辉.重视丙型肝炎的筛查.肝脏2007, 10 (12 ):333-334.
[7] Lau GKK, Zhuang H Top hepatology issue in China. J Gastroent Hepatol, 2003, 17 (SuppI):Ag.
[8] Slavenburg S, Verduyn-Lunel FM, Hermsen JT, et al. Prevalence of hepatitis C in the general population in the Netherlands. Neth J Med. 2008 Jan; 66 (1):13-17.
[9] Pérez CM, Albizu C, Pe?a M, et al, Hepatitis C in Puerto Rico: a time for public health action. P R Health Sci J. 2007 Dec;26 (4):395-400.
[10]Achwan WA, Muttaqin Z, Zakaria E, et al. Epidemiology of hepatitis B, C, and E viruses and human immunodeficiency virus infections in Tahuna, Sangihe-Talaud Archipelago, Indonesia. Intervirology. 2007;50(6):408-411.
[11]Hüppe D, Zehnter E, Mauss S, et al. Epidemiology of chronic hepatitis C in Germany--an analysis of 10, 326 patients in hepatitis centres and outpatient units Z Gastroenterol. 2008 Jan; 46(1):34-44.
[12]Groom H, Dieperink E, Nelson DB, et al. outcomes of a Hepatitis C screening program at a large urban VA medical center. J Clin Gastroenterol. 2008 Jan; 42 (1):97-106.
[13]Mansell CJ, Locarnini SA. Epidemiology of hepatitis C in East, Semin Liver Dis, 1995, 15:15-32.
[14]中华医学会肝病学分会.丙型肝炎防治指南[Z].中华流行病学, 2004, 2 (5) :369.
[15]Armstrong GL, Alter MJ, M CQ uillan GM, et al. The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. Hepatology, 2000, 31:777-782.
[16]Alter HJ, Seeff LB. Recovery, per sistence, and sequelae in heap-titis C virus infection : a perspective on long2term outcome [J]. Semin Liver Dis, 2000, 20 (1) : 17-35.
[17]中华医学会肝病学分会中华学会传染病与寄生虫病学分会,丙肝防治指南.中华肝脏病杂志, 2004(4).
[18]Alter MJ, Kruszon-Moran D, Nainan OV, etal. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999; 341: 556-562.
[19]Armstrong GL, Wasley A, Simard EP, etal. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006; 144: 705-714.
[20]Gerard C, Delwaide J, Vaira D, etal. Evolution over a 10 year period of the epidemiological profile of 1, 726 newly diagnosed HCV patients in Belgium. J Med Virol 2005; 76: 503-510.
[21]Touzet S, Kraemer L, Colin C, et al. Epidemiology of hepatitis C virus infection in seven European Union countries: a critical analysis of the literature. HENCORE Group (Hepatitis C European Network for Cooperative Research). Eur J Gastroenterol Hepatol 2000, 12: 667-678.
[22]Van Damme P, Thyssen A, Van Loock F. Epidemiology of hepatitis C in Belgium: present and future. Acta Gastroenterol Belg 2002, 5: 78-79.
[23]Bellentani S, Tiribelli C. The spectrum of liver disease in the general population: lesson from the Dionysos study. J Hepatol 2001, 35: 531-537.
[24]Pradat P. Prevalence of hepatitis C infection among general practice patients in the Lyon area, France. Eur J Epidemiol 2001, 17: 47-51.
[25]Theodore Sy, M. Mazen Jamal. Epidemiology of Hepatitis C Virus (HCV) Infection. Int. J. Med. Sci 2006, 3: 41-46.
[26]Perez CM, Suarez E, Torres EA, et al. Seroprevalence of hepatitis C virus and associated risk behaviours: a population based study in San Juan, Puerto Rico. Int J Epidemiol 2005, 34: 593-599.
[27]Tanaka J, Kumagai J, Katayama K, et al. Sex and age-specific carriers of hepatitis B and C viruses in Japan estimated by the prevalence in the 3, 485, 748 first-time blood donors during 1995-2000. Intervirology 2004, 47: 32-40.
[28]Madhava V. , Burgess C. , Drucker E. Epidemiology of chronic hepatitis C virus infection in sub-Saharan Africa. Lancet Infect Dis. 2002, 2: 293-302.
[29]Darwish MA, Faris R, Darwish N, et al. Hepatitis C and cirrhotic liver disease in the Nile delta of Egypt: A community-based study. Am J Trop Med Hyg 2001, 64:147-153.
[30]Mohamed MK, Bakr I, El-Hoseiny M, et al. HCV-Related Morbidity in a Rural Community of Egypt. Journal of Medical Virology 2006, 78: 1185-1189.
[31]Nafeh MA, Medhat A, Shehata M, et al. Hepatitis C in a community in Upper Egypt: I. Cross-sectional survey. Am J Trop Med Hyg 2000, 63: 236-241.
[32]DanisK, Doherty L, McCartney M, et al. Hepatitis and HIV in Northern Ireland prisons: a cross-sectional study. Euro Surveil. 2007 Jan 20; 12(1) [Epub ahead of print].
[33]罗耀星,张吉凯,李建基,等.广东省2002年病毒性肝炎血清流行病学调查分析.中国计划免疫, 2005, 4(11):89-92.
[34]李亮,刘社兰,朱凤才,等.江苏省病毒性肝炎血清流行病学调查研究.江苏预防医学, 2005, 9(16):21-23.
[35]赵文,费解明. 1024例肝病患者抗-HCV检测结果分析.现代中西医结合杂志, 2004, 9(13):3030-3032.
[36]闫鞍民,罗小铭,高赛珍. 306名健康人群乙丙丁戊型肝炎病毒感染血清学调查.实用预防医学2004, 6(11):482-483.
[37]何华先,王华洪,张大迁“二劳”人员中HBV ?HCV感染的血清流行病学调查.实用预防医学, 2006,2(1):94-95. [38?Klaus peter Maier.肝炎及其后果(译著,郝连杰).北京:人民卫生出版社, 2001.
[39]Bortolotti F, Resti M, Giacehino R, et al. Changing epidemiologic pattern of chronic hepatitis C virus infection in Italian children. J-Pediatr. 1998 SeP:133(3):378-381.
[40]佘为民,胡德昌,袁和俊,等.输血后HCV感染的前瞻性研究.中国临床医学, 2002, 9 (2) : 114-115.
[41]周枫,马泽恩,胡薇,等.静脉吸毒共用注射器具方式和性行为与丙型肝炎病毒感染关系的研究.中华流行病学杂志, 2004, 25 (4) :329-332.
[42]Qian HZ, Yang Z, Shi X, et al. Hepatitis C virus infection in former commercial plasmaPblood donors in Rural Shanxi Province, China: the China integrated programs for research on AIDS. Infect Dis, 2005, 192∶1694-1700.
[43] Chen YD, Liu MY, Yu WL, et al. Hepatitis C virus infections and genotypes in China. Hepatobiliary Pancreatic Diseases International, 2002, 1:194-201.
[44]郑淑鹏,庄坤玉,张云兰,等.筛查抗-HCV对单采浆献血员保护作用的评价.中国公共卫生, 1995, 11∶255-256.
[45]刘传德,姜开银,宋海翔.血液透析患者乙型肝炎和丙型肝炎病毒感染的血清学调查.中国中西医结合肾病学杂志, 2002, 3∶521-522.
[46]Garten RJ, Zhang J, Lai S, et al. Coinfection with HIV and hepatitis C virus amonginjection drug users in Southern China. Clin Infect Dis, 2005,41(Suppl 1):S18-24.
[47]Garten RJ, Lai S, Zhang J, et al. Rapid transmission of hepatitis C virus among young injecting heroin users in Southern China. Int J Epidemiol, 2004, 33∶182-188.
[48]朱彪,吴南屏,吴灵娇,等.浙江省吸毒人员HIV?HBV?HCV感染的血清学研究.中国公共卫生, 1999, 15∶415-416.
[49]颜瑾,曾常红,李晖,等.广东省1998年吸毒人群吸毒方式与艾滋病?丙型肝炎及梅毒的关系分析.中国性病艾滋病防治, 2000, 6∶338-339.
[50]Blajchman MA, Bull SB, Feinman SV. Post-transfusion hepatitis impact of non-B hepatitis surrogate tests. Canadian Post-transfusion Hepatitis Prevention Study Group Lancet 1995;345: 21-25.
[51]Pahuja S, Sharma M, Baitha B, et al?Prevalence and trends of markers of hepatitis C virus, hepatitis B virus and human immunodeficiency virus in Delhi blood donors: a hospital based study?Jpn J Infect Dis. 2007 Nov; 60(6):389-391.
[52]刘淑贞,傅继华,康殿民,等.山东某地区献血员丙型肝炎病毒感染状况调查.中国初级卫生保健, 2000, 14∶49-50.
[53]Winslow M, Subramania M Ng WL, Lee A, et al. Seroprevalence of hepatitis C in intravenous opioid users presenting in the early phase of injecting drug use in Singapore. , Singapore Med J. 2007 Jun;48(6):504-508.
[54]Rhodes T, Platt L, Maximova S. Prevalence of HIV, hepatitis C and syphilis among injecting drug users in Russia:a multi-city study. Addiction.2006 Feb;101(2):252-266.
[55]姚辉鸣,李新旭,阮玉华,等.四川省西昌市静脉吸毒人群丙型肝炎病毒感染情况研究.中国药物滥用防治杂志, 2007, 13, (2):67-69.
[56]孙艳,张琰,陈伟,等.吸毒人员中丙型肝炎病毒感染状况及其影响因素.职业与健康, 2007, 6(23):881-883.
[57]夏娴,骆峻,董静,等.江苏省部分地区吸毒人群HCV感染的流行病学调查.现代预防医学, 2007, 34(2):4616-4617.
[58]石长胜,艾宪淮,刘传新.泰安市职业献血员丙型肝炎病毒感染状况调查.中华实验和临床病毒学杂志, 2002, 16∶193-194.
[59]Ramarakoto CE Rakotomanana F, Ratsitorahina M, et al. Seroprevalence of hepatitis C and associated risk factors in urban areas of Antananarivo, Madagascar BMC Infect Dis. 2008 Feb 29;8(1):25.
[60]Rahnavardi M, Hosseini Moghaddam SM, Alavian SM. Hepatitis C in Hemodialysis Patients: Current Global Magnitude, Natural History, Diagnostic Difficulties, and Preventive Measures. Am J Nephrol. 2008 Feb 19;28(4):628-640.
[61]Fried MW, Shindo M, Fong TL, et al. Absence of hepatitis C viral RNA from saliva And semen of Patients with chronic hepatitis C. Gastroenterology, 1992, 102:1306-1308.
[62]Liou TC, Chang TT, Young KC, et al. Detection of HCVRNA in saliva, urine, seminal fluid, and as cites. J Med Virol, 1992, 37(3):197-202.
[63]Akhtar S, Moatter T. Multilevel modeling of intra-household spread of hepatitis C virus infection, Karachi, Pakistan. Am J Trop Med Hyg. 2007 Mar; 76(3):446-449.
[64]Lissen E, Alter HJ, Abad MA, et al. Hepatitis C virus infection among sexually promiscuous groups and the heterose xual partners of hepatitis C virus infected index cases·Eur J Clin Mierobiol Infect Dis, 1993, 12:827-831.
[65]王桂荣.慢性丙型肝炎患者体液HCV-RNA检测结果与传播途径分析.中国民康医学, 2007, 12(19):1041-1042.
[66]肖志明,张秀丽,刘生翔. 676名女性性服务者HIV?TP?HBsAg和HCV感染状况调查分析.疾病监测, 2006, 21∶445.
[67]王青,梁晓峰,陈园生.丙型病毒性肝炎的研究近况.国际检验医学杂志,2006, 4 (4):349-350.
[68]Hellard ME, Hocking JS, Crofts N. The prevalence and the risk behaviours associated with the transmissionof hepatitis C virus in Australian correction alfacilities. Epidemiol Infect 2004; 132:409-415.
[69]Nishioka SA, Gyorkos TW, Joseph L, et al. Tattooing and transfusion-transmitted diseases in Brazil: a hospital-based cross-sectional matched study. Eur J Epidemiol 2003; 18: 441-449.
[70]Haley RW, Fischer RP. The tattooing paradox: are studies of acute hepatitis adequate to identify routes of transmission of subclinical hepatitis C infection? Arch Intern Med 2003; 163: 1095-1098.
[71]王秀,李登清,黄民主,等.吸毒人员丙型肝炎病毒感染及其影响因素的研究.中华医学实践杂志,2005; 4: 20-21.
[72]高建忠,曾云,李通情,等.渭南市劳教人员8048例艾滋病?乙型及丙型肝炎的感染情况.职业与健康, 2006, 9 (17 ):1374-1375.
[73]周炳华,张琼.新疆地区不同人群丙型肝炎病毒感染状况分析-附3012份检测结果.新医学,1999, 3(30):152-153.
[1]王豪,丙型肝炎的流行病学与预防.中华肝脏病杂志, 2003, 6(6):366-367.
[2]中华医学会肝病学分会中华学会传染病与寄生虫病学分会,丙肝防治指南.中华肝脏病杂志, 2004(4)
[3]李克.丙型肝炎病毒与脂质系统关系的研究进展[J]国外医学病毒学册, 2002;9(1), 167-169.
[4]中华医学会肝病学分会,丙型肝炎防治指南.中华流行病学, 2004, 2(5) :3691.
[5]李慧霞,丹东地区部分人群HCV感染状况的调查.现代医药卫生, 2006, 22(11):1751.
[6]赵树铭,李兵,胡建,等.重庆地区无偿献血人群丙型肝炎病毒流行病学调查.重庆医学, 2006, 6(35 ):964-966.
[7]蔡汉港,李晖,罗耀星,等?广东省丙型和戊型肝炎血清流行病学调查.华南预防医学, 2003, 10(29):35-36.
[8]李秋岭李华张成新,输血前患者与无偿献血者相关传染病检测结果报告.中国临床实用医学, 2007, 6(1):68-69.
[9]王海燕,杨忠思,李延年?青岛地区输血前患者与无偿献血者输血相关传染病的流行性分析?中国输血杂志, 2005, (18). 53-54
[10]陆建华陈建国朱健,等.不同人群HCV与其它肝病标志物阳性率的调查.公共卫生与预防医学, 2007, 18(6):34-36.
[11]杨丙辛,李伍升,刘玉振?郑州地区无偿献血者年龄性别分布调查?职业与健康, 2005, 10(21):1523-1524.
[12]王青,胡联友,赵代虹,等?重庆市丙型病毒性肝炎血清流行病学调查,预防医学情报杂志. 2007, 4(23):152-154.
[13]李丽,张建琼,夏梅,等.血液透析患者丙型肝炎病毒特异性PCR基因分型.临床检验杂志, 2003, 21 (4): 196-198.
[14]Walkerpeach CR, Winkler M, Dubois DB, et al. Ribonuclease resistant RNA controls (Armored RNA) for reverse transcription-PCR, branched DNA, and genotyping assays for hepatitis C virus. Clin Chem, 1999, 45(12): 2079-2085·
[15]Park JS, Saraf N, Dieterich DT. HBV plus HCV, HCV plus HIV, HBV plus HIV. Curr Gastroenterol Rep, 2006, 8∶67274.
[16]洪楷,丁映淑,陈林兴,等.不同人群感染丙型及庚型肝炎病毒危险性分析.中国公共卫生, 2006, 22∶346-347.
[17]Simmonds P, Holmes EC, Cha TA, etal. Classification of hepatitis C virus into sixmajor genotypes and a series of subtypes by phylogenetic analysis of theNS一5 region. J Gen Virol, 1993, 74:2391
[18]Simmonds P, Bukh J, Combet C, etal. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology, 2005, 42:962-973.
[19]Chan S-W, Hocomish f, Hiolmes EC. Analysis of a new hepatitis C virus and its phylogenetic relationship to existing variants[J]. J Gen Virol, 1992, 73(5):1131-1141.
[20]Bukh J, Robert H, Purcell, Roger H. At least 12 genotypes of hepatitis C virus predicted by sequence analysis of the putative E1 gene of isolates collected worldwide[J]. Pro. Natl. Acad. Sci. USA 1993, 90(17)8234-8248.
[21]Tokita H, Okamoto H, Tsuda F. Hepatitis C virus variants from Vietnam are classifiable into the seventh eighth and ninth major genetic group[J]. Pro. Natl. Acad. Sci. USA 1994, 91(23):11022-11026.
[22]EnomotoN, etal. There are two major types of hepatitis C virus in Japan. Biochem Biophys Res common 1990;170:1021
[23]MoriS, etal. A new type of hepatitis C virus in patients in Thailand. Biochem Biophys Res common 1992;183:334
[24]Simmonds P etal. Classification of hepatitis C vieus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS5 regin. J Gen Virol. 1992;73:673
[25]OkamotoH, etal. Typing hepatitis C virus by polymerase chain reaction with type specific primers:Application to clinical surveys and tracing infectious sources. J Gen virol. 1992;73:673
[26]OkamotoH, eta了. The entire nucleotide sequence and classification of a hepatitis C virus isolate of a novel genotype from an indoncsian patient with chronic liver diease. J Gen virol 1994;75:629
[27]Stuyver L, etal. Typing of hepatitis C virus iolate and characterization of newsubtype using a line probe assay. J Gen virol 1993;74:1093-46
[28]Simmonds P, etal. Sequence variability of the 5'non-coding region of hepatitis C virus identification of a new type and restriction on sequence diversity. J Gen Virol. 1993;74:661
[29]Chen TA, et al. At least five related but distinct hepatitis C virus genotype exist. Proc Natl Acad Sci USA1992;89:7149
[30]LIEW M, ERALI M, PAGE S, et al. Hepatitis C genotyping by denaturing high-performance liquid chromatography[J]. Clin Microbiol, 2004, 42(1):158.
[31]NIZAR N. Zein. Clinical significance of hepatitis C virus genotypes[J]. Clin Microbiol Rev, 2000, 13(2):223-235.
[32]王全力, HCV基因分型研究进展.国外医学病毒学分册, 2002, 9(3):93-95.
[33]张帆,王小红,王宇明,等.重庆地区HCV基因亚型的分布状态.第四军医大学学报, 2006, 26(14):1253-1255.
[34]胡斌,张孝文,程钢,等.广东地区丙型肝炎患者的HCV基因分型研究.热带医学杂志, 2006, 10(10):1071-1073.
[35]曹金德,王跃国,施英娟,等.南通地区慢性丙型肝炎患者的HCV基因分型.中国交通医学杂志, 2005, 19(1):75-77.
[36]魏来,亚太地区丙型肝炎病毒感染的诊断?处理和治疗共识.临床肝胆病杂志, 2007, 23(5):323-325.
[37]屈莉红,陈良,王介非. HCVNS3蛋白酶及抑制剂的研究进展.肝脏, 2007, 6(3):203-205.
[38]Kneteman NM, Weiner AJ, O’Connell J, el al. Anti2HCV therapies in chimeric scid2AlbPuPA mice parallel outcomes in human clinicalapplication. Hepatology, 2006, 43∶134621353.
[39]Hinrichsen H, Benhamou Y, Wedemeyer H, et al. Short2term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. Gastroenterology, 2004, 127∶1347 -1355.
[40]Tong X, Guo Z, Wright2Minogue J, et al. Impact of naturally occurring variants of HCV protease on the binding of different classes of protease inhibitors. Biochemistry, 2006, 45∶1353 - 1361.
[41]Zeuzem S, Sarrazin C, Rouzier R, et al. Anti2viral activity of SCH 503034, a HCV protease inhibitor, administered as monotherapy in hepatitis C genotype21 (HCV21) patients refractory to pegylated interferon (Peg2IFN2a). Hepatology, 2005, 42∶233A
[2]刘锡光主编.病毒性肝炎实验诊断学,第二版.北京:人民卫生出版社, 1999.
[3] Perz JF, Farrington LA, Pecoraro C, et al. Estimated global prevalence of hepatitis C virus infection. 42nd Annual Meeting of the Infectious Diseases Society of America ; Boston, MA, USA; Sept 302Oct 3, 2004.
[4] 2007年亚太肝病学会有关丙型肝炎诊断?处理和治疗的共识.传染病信息, 2007, 20(3) R 187-189.
[5] Freeman AL, Zekry A, Whybin LR, et al. Hepatitis C prevalence among Australianinjeetingdrugusersinthe19705andProfilesofvirusgenotyPein the19705 and 19905. Med-J-Aust. 2000Jun19:172(12):588-91.
[6]石爽,庄辉.重视丙型肝炎的筛查.肝脏2007, 10 (12 ):333-334.
[7] Lau GKK, Zhuang H Top hepatology issue in China. J Gastroent Hepatol, 2003, 17 (SuppI):Ag.
[8] Slavenburg S, Verduyn-Lunel FM, Hermsen JT, et al. Prevalence of hepatitis C in the general population in the Netherlands. Neth J Med. 2008 Jan; 66 (1):13-17.
[9] Pérez CM, Albizu C, Pe?a M, et al, Hepatitis C in Puerto Rico: a time for public health action. P R Health Sci J. 2007 Dec;26 (4):395-400.
[10]Achwan WA, Muttaqin Z, Zakaria E, et al. Epidemiology of hepatitis B, C, and E viruses and human immunodeficiency virus infections in Tahuna, Sangihe-Talaud Archipelago, Indonesia. Intervirology. 2007;50(6):408-411.
[11]Hüppe D, Zehnter E, Mauss S, et al. Epidemiology of chronic hepatitis C in Germany--an analysis of 10, 326 patients in hepatitis centres and outpatient units Z Gastroenterol. 2008 Jan; 46(1):34-44.
[12]Groom H, Dieperink E, Nelson DB, et al. outcomes of a Hepatitis C screening program at a large urban VA medical center. J Clin Gastroenterol. 2008 Jan; 42 (1):97-106.
[13]Mansell CJ, Locarnini SA. Epidemiology of hepatitis C in East, Semin Liver Dis, 1995, 15:15-32.
[14]中华医学会肝病学分会.丙型肝炎防治指南[Z].中华流行病学, 2004, 2 (5) :369.
[15]Armstrong GL, Alter MJ, M CQ uillan GM, et al. The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. Hepatology, 2000, 31:777-782.
[16]Alter HJ, Seeff LB. Recovery, per sistence, and sequelae in heap-titis C virus infection : a perspective on long2term outcome [J]. Semin Liver Dis, 2000, 20 (1) : 17-35.
[17]中华医学会肝病学分会中华学会传染病与寄生虫病学分会,丙肝防治指南.中华肝脏病杂志, 2004(4).
[18]Alter MJ, Kruszon-Moran D, Nainan OV, etal. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999; 341: 556-562.
[19]Armstrong GL, Wasley A, Simard EP, etal. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006; 144: 705-714.
[20]Gerard C, Delwaide J, Vaira D, etal. Evolution over a 10 year period of the epidemiological profile of 1, 726 newly diagnosed HCV patients in Belgium. J Med Virol 2005; 76: 503-510.
[21]Touzet S, Kraemer L, Colin C, et al. Epidemiology of hepatitis C virus infection in seven European Union countries: a critical analysis of the literature. HENCORE Group (Hepatitis C European Network for Cooperative Research). Eur J Gastroenterol Hepatol 2000, 12: 667-678.
[22]Van Damme P, Thyssen A, Van Loock F. Epidemiology of hepatitis C in Belgium: present and future. Acta Gastroenterol Belg 2002, 5: 78-79.
[23]Bellentani S, Tiribelli C. The spectrum of liver disease in the general population: lesson from the Dionysos study. J Hepatol 2001, 35: 531-537.
[24]Pradat P. Prevalence of hepatitis C infection among general practice patients in the Lyon area, France. Eur J Epidemiol 2001, 17: 47-51.
[25]Theodore Sy, M. Mazen Jamal. Epidemiology of Hepatitis C Virus (HCV) Infection. Int. J. Med. Sci 2006, 3: 41-46.
[26]Perez CM, Suarez E, Torres EA, et al. Seroprevalence of hepatitis C virus and associated risk behaviours: a population based study in San Juan, Puerto Rico. Int J Epidemiol 2005, 34: 593-599.
[27]Tanaka J, Kumagai J, Katayama K, et al. Sex and age-specific carriers of hepatitis B and C viruses in Japan estimated by the prevalence in the 3, 485, 748 first-time blood donors during 1995-2000. Intervirology 2004, 47: 32-40.
[28]Madhava V. , Burgess C. , Drucker E. Epidemiology of chronic hepatitis C virus infection in sub-Saharan Africa. Lancet Infect Dis. 2002, 2: 293-302.
[29]Darwish MA, Faris R, Darwish N, et al. Hepatitis C and cirrhotic liver disease in the Nile delta of Egypt: A community-based study. Am J Trop Med Hyg 2001, 64:147-153.
[30]Mohamed MK, Bakr I, El-Hoseiny M, et al. HCV-Related Morbidity in a Rural Community of Egypt. Journal of Medical Virology 2006, 78: 1185-1189.
[31]Nafeh MA, Medhat A, Shehata M, et al. Hepatitis C in a community in Upper Egypt: I. Cross-sectional survey. Am J Trop Med Hyg 2000, 63: 236-241.
[32]DanisK, Doherty L, McCartney M, et al. Hepatitis and HIV in Northern Ireland prisons: a cross-sectional study. Euro Surveil. 2007 Jan 20; 12(1) [Epub ahead of print].
[33]罗耀星,张吉凯,李建基,等.广东省2002年病毒性肝炎血清流行病学调查分析.中国计划免疫, 2005, 4(11):89-92.
[34]李亮,刘社兰,朱凤才,等.江苏省病毒性肝炎血清流行病学调查研究.江苏预防医学, 2005, 9(16):21-23.
[35]赵文,费解明. 1024例肝病患者抗-HCV检测结果分析.现代中西医结合杂志, 2004, 9(13):3030-3032.
[36]闫鞍民,罗小铭,高赛珍. 306名健康人群乙丙丁戊型肝炎病毒感染血清学调查.实用预防医学2004, 6(11):482-483.
[37]何华先,王华洪,张大迁“二劳”人员中HBV ?HCV感染的血清流行病学调查.实用预防医学, 2006,2(1):94-95. [38?Klaus peter Maier.肝炎及其后果(译著,郝连杰).北京:人民卫生出版社, 2001.
[39]Bortolotti F, Resti M, Giacehino R, et al. Changing epidemiologic pattern of chronic hepatitis C virus infection in Italian children. J-Pediatr. 1998 SeP:133(3):378-381.
[40]佘为民,胡德昌,袁和俊,等.输血后HCV感染的前瞻性研究.中国临床医学, 2002, 9 (2) : 114-115.
[41]周枫,马泽恩,胡薇,等.静脉吸毒共用注射器具方式和性行为与丙型肝炎病毒感染关系的研究.中华流行病学杂志, 2004, 25 (4) :329-332.
[42]Qian HZ, Yang Z, Shi X, et al. Hepatitis C virus infection in former commercial plasmaPblood donors in Rural Shanxi Province, China: the China integrated programs for research on AIDS. Infect Dis, 2005, 192∶1694-1700.
[43] Chen YD, Liu MY, Yu WL, et al. Hepatitis C virus infections and genotypes in China. Hepatobiliary Pancreatic Diseases International, 2002, 1:194-201.
[44]郑淑鹏,庄坤玉,张云兰,等.筛查抗-HCV对单采浆献血员保护作用的评价.中国公共卫生, 1995, 11∶255-256.
[45]刘传德,姜开银,宋海翔.血液透析患者乙型肝炎和丙型肝炎病毒感染的血清学调查.中国中西医结合肾病学杂志, 2002, 3∶521-522.
[46]Garten RJ, Zhang J, Lai S, et al. Coinfection with HIV and hepatitis C virus amonginjection drug users in Southern China. Clin Infect Dis, 2005,41(Suppl 1):S18-24.
[47]Garten RJ, Lai S, Zhang J, et al. Rapid transmission of hepatitis C virus among young injecting heroin users in Southern China. Int J Epidemiol, 2004, 33∶182-188.
[48]朱彪,吴南屏,吴灵娇,等.浙江省吸毒人员HIV?HBV?HCV感染的血清学研究.中国公共卫生, 1999, 15∶415-416.
[49]颜瑾,曾常红,李晖,等.广东省1998年吸毒人群吸毒方式与艾滋病?丙型肝炎及梅毒的关系分析.中国性病艾滋病防治, 2000, 6∶338-339.
[50]Blajchman MA, Bull SB, Feinman SV. Post-transfusion hepatitis impact of non-B hepatitis surrogate tests. Canadian Post-transfusion Hepatitis Prevention Study Group Lancet 1995;345: 21-25.
[51]Pahuja S, Sharma M, Baitha B, et al?Prevalence and trends of markers of hepatitis C virus, hepatitis B virus and human immunodeficiency virus in Delhi blood donors: a hospital based study?Jpn J Infect Dis. 2007 Nov; 60(6):389-391.
[52]刘淑贞,傅继华,康殿民,等.山东某地区献血员丙型肝炎病毒感染状况调查.中国初级卫生保健, 2000, 14∶49-50.
[53]Winslow M, Subramania M Ng WL, Lee A, et al. Seroprevalence of hepatitis C in intravenous opioid users presenting in the early phase of injecting drug use in Singapore. , Singapore Med J. 2007 Jun;48(6):504-508.
[54]Rhodes T, Platt L, Maximova S. Prevalence of HIV, hepatitis C and syphilis among injecting drug users in Russia:a multi-city study. Addiction.2006 Feb;101(2):252-266.
[55]姚辉鸣,李新旭,阮玉华,等.四川省西昌市静脉吸毒人群丙型肝炎病毒感染情况研究.中国药物滥用防治杂志, 2007, 13, (2):67-69.
[56]孙艳,张琰,陈伟,等.吸毒人员中丙型肝炎病毒感染状况及其影响因素.职业与健康, 2007, 6(23):881-883.
[57]夏娴,骆峻,董静,等.江苏省部分地区吸毒人群HCV感染的流行病学调查.现代预防医学, 2007, 34(2):4616-4617.
[58]石长胜,艾宪淮,刘传新.泰安市职业献血员丙型肝炎病毒感染状况调查.中华实验和临床病毒学杂志, 2002, 16∶193-194.
[59]Ramarakoto CE Rakotomanana F, Ratsitorahina M, et al. Seroprevalence of hepatitis C and associated risk factors in urban areas of Antananarivo, Madagascar BMC Infect Dis. 2008 Feb 29;8(1):25.
[60]Rahnavardi M, Hosseini Moghaddam SM, Alavian SM. Hepatitis C in Hemodialysis Patients: Current Global Magnitude, Natural History, Diagnostic Difficulties, and Preventive Measures. Am J Nephrol. 2008 Feb 19;28(4):628-640.
[61]Fried MW, Shindo M, Fong TL, et al. Absence of hepatitis C viral RNA from saliva And semen of Patients with chronic hepatitis C. Gastroenterology, 1992, 102:1306-1308.
[62]Liou TC, Chang TT, Young KC, et al. Detection of HCVRNA in saliva, urine, seminal fluid, and as cites. J Med Virol, 1992, 37(3):197-202.
[63]Akhtar S, Moatter T. Multilevel modeling of intra-household spread of hepatitis C virus infection, Karachi, Pakistan. Am J Trop Med Hyg. 2007 Mar; 76(3):446-449.
[64]Lissen E, Alter HJ, Abad MA, et al. Hepatitis C virus infection among sexually promiscuous groups and the heterose xual partners of hepatitis C virus infected index cases·Eur J Clin Mierobiol Infect Dis, 1993, 12:827-831.
[65]王桂荣.慢性丙型肝炎患者体液HCV-RNA检测结果与传播途径分析.中国民康医学, 2007, 12(19):1041-1042.
[66]肖志明,张秀丽,刘生翔. 676名女性性服务者HIV?TP?HBsAg和HCV感染状况调查分析.疾病监测, 2006, 21∶445.
[67]王青,梁晓峰,陈园生.丙型病毒性肝炎的研究近况.国际检验医学杂志,2006, 4 (4):349-350.
[68]Hellard ME, Hocking JS, Crofts N. The prevalence and the risk behaviours associated with the transmissionof hepatitis C virus in Australian correction alfacilities. Epidemiol Infect 2004; 132:409-415.
[69]Nishioka SA, Gyorkos TW, Joseph L, et al. Tattooing and transfusion-transmitted diseases in Brazil: a hospital-based cross-sectional matched study. Eur J Epidemiol 2003; 18: 441-449.
[70]Haley RW, Fischer RP. The tattooing paradox: are studies of acute hepatitis adequate to identify routes of transmission of subclinical hepatitis C infection? Arch Intern Med 2003; 163: 1095-1098.
[71]王秀,李登清,黄民主,等.吸毒人员丙型肝炎病毒感染及其影响因素的研究.中华医学实践杂志,2005; 4: 20-21.
[72]高建忠,曾云,李通情,等.渭南市劳教人员8048例艾滋病?乙型及丙型肝炎的感染情况.职业与健康, 2006, 9 (17 ):1374-1375.
[73]周炳华,张琼.新疆地区不同人群丙型肝炎病毒感染状况分析-附3012份检测结果.新医学,1999, 3(30):152-153.
[1]王豪,丙型肝炎的流行病学与预防.中华肝脏病杂志, 2003, 6(6):366-367.
[2]中华医学会肝病学分会中华学会传染病与寄生虫病学分会,丙肝防治指南.中华肝脏病杂志, 2004(4)
[3]李克.丙型肝炎病毒与脂质系统关系的研究进展[J]国外医学病毒学册, 2002;9(1), 167-169.
[4]中华医学会肝病学分会,丙型肝炎防治指南.中华流行病学, 2004, 2(5) :3691.
[5]李慧霞,丹东地区部分人群HCV感染状况的调查.现代医药卫生, 2006, 22(11):1751.
[6]赵树铭,李兵,胡建,等.重庆地区无偿献血人群丙型肝炎病毒流行病学调查.重庆医学, 2006, 6(35 ):964-966.
[7]蔡汉港,李晖,罗耀星,等?广东省丙型和戊型肝炎血清流行病学调查.华南预防医学, 2003, 10(29):35-36.
[8]李秋岭李华张成新,输血前患者与无偿献血者相关传染病检测结果报告.中国临床实用医学, 2007, 6(1):68-69.
[9]王海燕,杨忠思,李延年?青岛地区输血前患者与无偿献血者输血相关传染病的流行性分析?中国输血杂志, 2005, (18). 53-54
[10]陆建华陈建国朱健,等.不同人群HCV与其它肝病标志物阳性率的调查.公共卫生与预防医学, 2007, 18(6):34-36.
[11]杨丙辛,李伍升,刘玉振?郑州地区无偿献血者年龄性别分布调查?职业与健康, 2005, 10(21):1523-1524.
[12]王青,胡联友,赵代虹,等?重庆市丙型病毒性肝炎血清流行病学调查,预防医学情报杂志. 2007, 4(23):152-154.
[13]李丽,张建琼,夏梅,等.血液透析患者丙型肝炎病毒特异性PCR基因分型.临床检验杂志, 2003, 21 (4): 196-198.
[14]Walkerpeach CR, Winkler M, Dubois DB, et al. Ribonuclease resistant RNA controls (Armored RNA) for reverse transcription-PCR, branched DNA, and genotyping assays for hepatitis C virus. Clin Chem, 1999, 45(12): 2079-2085·
[15]Park JS, Saraf N, Dieterich DT. HBV plus HCV, HCV plus HIV, HBV plus HIV. Curr Gastroenterol Rep, 2006, 8∶67274.
[16]洪楷,丁映淑,陈林兴,等.不同人群感染丙型及庚型肝炎病毒危险性分析.中国公共卫生, 2006, 22∶346-347.
[17]Simmonds P, Holmes EC, Cha TA, etal. Classification of hepatitis C virus into sixmajor genotypes and a series of subtypes by phylogenetic analysis of theNS一5 region. J Gen Virol, 1993, 74:2391
[18]Simmonds P, Bukh J, Combet C, etal. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology, 2005, 42:962-973.
[19]Chan S-W, Hocomish f, Hiolmes EC. Analysis of a new hepatitis C virus and its phylogenetic relationship to existing variants[J]. J Gen Virol, 1992, 73(5):1131-1141.
[20]Bukh J, Robert H, Purcell, Roger H. At least 12 genotypes of hepatitis C virus predicted by sequence analysis of the putative E1 gene of isolates collected worldwide[J]. Pro. Natl. Acad. Sci. USA 1993, 90(17)8234-8248.
[21]Tokita H, Okamoto H, Tsuda F. Hepatitis C virus variants from Vietnam are classifiable into the seventh eighth and ninth major genetic group[J]. Pro. Natl. Acad. Sci. USA 1994, 91(23):11022-11026.
[22]EnomotoN, etal. There are two major types of hepatitis C virus in Japan. Biochem Biophys Res common 1990;170:1021
[23]MoriS, etal. A new type of hepatitis C virus in patients in Thailand. Biochem Biophys Res common 1992;183:334
[24]Simmonds P etal. Classification of hepatitis C vieus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS5 regin. J Gen Virol. 1992;73:673
[25]OkamotoH, etal. Typing hepatitis C virus by polymerase chain reaction with type specific primers:Application to clinical surveys and tracing infectious sources. J Gen virol. 1992;73:673
[26]OkamotoH, eta了. The entire nucleotide sequence and classification of a hepatitis C virus isolate of a novel genotype from an indoncsian patient with chronic liver diease. J Gen virol 1994;75:629
[27]Stuyver L, etal. Typing of hepatitis C virus iolate and characterization of newsubtype using a line probe assay. J Gen virol 1993;74:1093-46
[28]Simmonds P, etal. Sequence variability of the 5'non-coding region of hepatitis C virus identification of a new type and restriction on sequence diversity. J Gen Virol. 1993;74:661
[29]Chen TA, et al. At least five related but distinct hepatitis C virus genotype exist. Proc Natl Acad Sci USA1992;89:7149
[30]LIEW M, ERALI M, PAGE S, et al. Hepatitis C genotyping by denaturing high-performance liquid chromatography[J]. Clin Microbiol, 2004, 42(1):158.
[31]NIZAR N. Zein. Clinical significance of hepatitis C virus genotypes[J]. Clin Microbiol Rev, 2000, 13(2):223-235.
[32]王全力, HCV基因分型研究进展.国外医学病毒学分册, 2002, 9(3):93-95.
[33]张帆,王小红,王宇明,等.重庆地区HCV基因亚型的分布状态.第四军医大学学报, 2006, 26(14):1253-1255.
[34]胡斌,张孝文,程钢,等.广东地区丙型肝炎患者的HCV基因分型研究.热带医学杂志, 2006, 10(10):1071-1073.
[35]曹金德,王跃国,施英娟,等.南通地区慢性丙型肝炎患者的HCV基因分型.中国交通医学杂志, 2005, 19(1):75-77.
[36]魏来,亚太地区丙型肝炎病毒感染的诊断?处理和治疗共识.临床肝胆病杂志, 2007, 23(5):323-325.
[37]屈莉红,陈良,王介非. HCVNS3蛋白酶及抑制剂的研究进展.肝脏, 2007, 6(3):203-205.
[38]Kneteman NM, Weiner AJ, O’Connell J, el al. Anti2HCV therapies in chimeric scid2AlbPuPA mice parallel outcomes in human clinicalapplication. Hepatology, 2006, 43∶134621353.
[39]Hinrichsen H, Benhamou Y, Wedemeyer H, et al. Short2term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. Gastroenterology, 2004, 127∶1347 -1355.
[40]Tong X, Guo Z, Wright2Minogue J, et al. Impact of naturally occurring variants of HCV protease on the binding of different classes of protease inhibitors. Biochemistry, 2006, 45∶1353 - 1361.
[41]Zeuzem S, Sarrazin C, Rouzier R, et al. Anti2viral activity of SCH 503034, a HCV protease inhibitor, administered as monotherapy in hepatitis C genotype21 (HCV21) patients refractory to pegylated interferon (Peg2IFN2a). Hepatology, 2005, 42∶233A
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |